Countries Raise Concern About ‘Fake Rabies Vaccine’ in India

A Counterfeit Crisis: What the Abhayrab Vaccine Controversy Reveals About India's Regulatory Gaps

The numbers are chilling: India accounts for 36% of global rabies deaths, with an estimated 18,000–20,000 annual fatalities, and two-thirds of victims aged under 15, according to the WHO. Against this backdrop, recent advisories from the UK, US, and Australia about counterfeit batches of Abhayrab, a rabies vaccine manufactured by the government-owned Indian Immunologicals Limited (IIL), have exposed vulnerabilities not just in vaccine manufacturing but in regulatory oversight. This is not a mere administrative hiccup; it’s an ethical and policy crisis that threatens public health at multiple levels.

At the heart of the controversy lies a counterfeit lot of Abhayrab, one of the most widely used rabies vaccines in India—covering 40% of the domestic market and exported to 40 countries. IIL claims it was the company’s own detection processes in January 2025 that brought the issue to light, after which regulatory authorities were informed, and the batch was reportedly withdrawn from sale. Yet, this assurance does little to mitigate the ethical quandary and systemic failure evident in allowing fake vaccines to infiltrate the supply chain in the first place. For a nation grappling with both the human and zoonotic toll of rabies, this raises an uncomfortable question: How did the counterfeit vaccines evade regulatory scrutiny in a sector so critical?

The High Stakes of Rabies Control

Rabies is almost 100% fatal once symptoms appear. The only effective intervention is timely post-exposure vaccination. India’s National Rabies Control Program recorded 6,644 suspected rabies deaths from 2012 to 2022, but the discrepancy with the WHO’s estimates suggests a failure of surveillance systems parallel to regulatory lapses in vaccine monitoring. Public trust in vaccines becomes even more critical when nearly two-thirds of bites come from unvaccinated dogs in rural areas, making accessible and reliable post-exposure prophylaxis (PEP) a necessity.

Abhayrab has long been a staple in India’s fight against rabies. Yet, the alteration of packaging and falsified batch information for a product as essential as this is a horrifying breach of trust, compounded by its widespread use in government programs and among vulnerable populations like children. A single failure here could cascade—undermining the credibility of not only rabies vaccines but public health initiatives, including polio vaccinations and COVID-19 boosters, in rural and urban communities alike.

The Systemic Weaknesses Exposed

At the core of the Abhayrab scandal lies the inadequate performance of regulatory bodies, particularly the Central Drugs Standard Control Organization (CDSCO) and its state counterparts, which are tasked with enforcing the Drugs and Cosmetics Act, 1940. Despite the Act’s stringent provisions against the distribution of counterfeit medicines, which can invite up to life imprisonment, lapses in routine inspections and the absence of robust monitoring frameworks like pharmaceutical serialization leave the system perennially exposed to manipulation.

While IIL's claim of timely self-regulation may mitigate some reputational damage, it also begs the question: Why was it left to a single manufacturer to identify such a critical breach? Furthermore, there is the glaring asymmetry in enforcement. Counterfeit pharmaceuticals are not new to India—the 59th Parliamentary Committee highlighted similar issues in 2012—but systemic reforms to address weak regulations remain conspicuously absent. The irony here is that India, a major vaccine exporter and global medicine hub, cannot seem to ensure verifiable safety within its own borders.

Another layer of failure emerges in the question of accountability. The rabies vaccine is predominantly used in government-run health programs or disseminated by state health departments. Medical professionals across both urban and rural settings unwittingly administered what they believed to be genuine vaccines. This situation underscores a widespread failure of institutional ethics, one that cannot merely blame individuals but must also scrutinize the state supply chain.

The International Contrast: How Thailand Does it Better

Consider Thailand, a country that shares India’s burden of rabies but takes a markedly different approach to vaccine regulation. The Thai Food and Drug Administration employs blockchain technology for tracking pharmaceuticals, ensuring that every unit—from factory to patient—has an auditable trail. Additionally, the country mandates a robust pharmacovigilance program with mandatory reporting of adverse events after vaccine administration. These measures ensure tighter control over quality and distribution, drastically reducing the likelihood of counterfeit or compromised vaccines entering the healthcare system.

India’s regulators have flirted with such ideas—experts from premier institutions like ICMR and AIIMS have proposed blockchain-based traceability mechanisms. But meaningful implementation is slow, hamstrung by bureaucratic inertia, underfunding, and limited accountability. The Abhayrab episode underscores the costs of this delay and should be a push towards not just adopting but also scaling such systems nationwide.

Rebuilding Trust Amidst Credibility Concerns

The greatest risk now is erosion of trust. Fake rabies vaccines will make communities more suspicious of all immunisation initiatives, potentially undoing years of hard-won progress in public health. The damage is intensified by the knowledge that at least some rural populations already mistrust modern medicine, often leaning toward traditional remedies or delaying treatment until it is fatalistically too late.

To restore credibility, piecemeal responses are not enough. More resources need to be directed toward strengthening supply chain auditing mechanisms, conducting biosurveillance, and holding pharmaceutical intermediaries—those who doctored the packaging in this case—criminally accountable. Beyond punishment, this is a moment for systemic reform. Investment in a digital traceability mechanism, public disclosure norms for counterfeit incidents, and third-party validations should no longer be framed as future aspirations but immediate imperatives.

India’s ambitions of becoming a global pharmaceuticals superpower hinge not just on cost advantages but on trust and compliance. If public health campaigns are to succeed, the system needs to close the governance and ethical fault lines revealed by this scandal.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions